pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: Cardiovascular

Aug 3, 2023

Results from XyloCor Therapeutics’ Phase 1 Portion of EXACT Trial of XC001 for Cardiovascular Disease Published in Circulation: Cardiovascular Interventions

Jul 18, 2023

XyloCor Therapeutics Reports Sustained Results in 12-Month Extension of Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina

Feb 24, 2023

Orchestra BioMed Announces Peer-Reviewed Publication of MODERATO II Study Results Showing a Statistically Significant Reduction in Blood Pressure in Pacemaker-Indicated Patients Treated with BackBeat Cardiac Neuromodulation Therapy

Jan 26, 2023

XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina

Dec 5, 2022

Fractyl Health Announced Positive Proof-of-Concept Data of Pancreatic GLP-1 Gene Therapy in a Type 2 Diabetes Animal Model at the 20th World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease

Nov 23, 2022

NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients

Nov 2, 2022

LEXEO Therapeutics Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment and Formation of Scientific Advisory Board

Sep 20, 2022

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

Sep 13, 2022

Eligo Bioscience and Kantonsspital St. Gallen announce their strategic alliance to address inflammatory cardiac diseases through in vivo gene editing

Aug 11, 2022

NewAmsterdam Pharma Announces Publication in Nature Medicine Discussing Clinical Potential of Obicetrapib

Jul 28, 2022

NewAmsterdam Pharma Doses First Patient in Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

Jul 25, 2022

NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases

Jun 28, 2022

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

Jun 28, 2022

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe USA - English España - español USA - English Latin America - español

Apr 11, 2022

Kyttaro Announces Worldwide Exclusive Licensing Agreement With Lilly for Antibody Therapeutic Program

Mar 2, 2022

Cardior Appoints Cardiac Disease and RNA Drug Development Experts to its Scientific Advisory Board Supporting Pipeline Expansion in Both Large and Orphan Cardiac Indications

Mar 1, 2022

NewAmsterdam Pharma Doses First Patient in PREVAIL, the Cardiovascular Outcomes Trial of Obicetrapib in Adults with Atherosclerotic Cardiovascular Disease (ASCVD)

Feb 16, 2022

LEXEO Therapeutics Announces FDA Clearance of Investigational New Drug Application for LX2006, an AAV-based Gene Therapy Candidate for Friedreich’s Ataxia Cardiomyopathy

Feb 9, 2022

Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants

Jan 18, 2022

Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio

Jan 4, 2022

NewAmsterdam Pharma Doses First Patient in Phase 3 BROADWAY Trial of Obicetrapib in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) and/or Established Atherosclerotic Cardiovascular Disease (ASCVD)

Dec 20, 2021

ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases

Dec 1, 2021

Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle

Nov 1, 2021

Rivus Pharmaceuticals Announces Positive Results from Phase 1 Trial of Lead Candidate HU6, Demonstrating Safety, Efficacy in Key Targets for Multiple Cardio-Metabolic Diseases

Oct 27, 2021

Cardurion Pharmaceuticals Announces Investment of up to $300 Million From Bain Capital

Oct 26, 2021

HiberCell and Strasbourg Institute for Precision Medicine Publish Machine Learning Data and Approach on Causal Biology of Severe COVID-19

Aug 25, 2021

Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

Aug 17, 2021

Orchestra BioMed™ Announces Peer-Reviewed Publication of MODERATO II Study Results Showing a Statistically Significant Reduction in Blood Pressure in Pacemaker-Indicated Patients Treated with BackBeat Cardiac Neuromodulation Therapy™

Jul 30, 2021

Orchestra BioMed™ Announces Clinical Data Demonstrating a Significant and Sustained Reduction in Blood Pressure in MODERATO II Control Patients After Crossover to BackBeat Cardiac Neuromodulation Therapy™

Jul 30, 2021

Orchestra BioMed Announces Clinical Data Demonstrating a Significant and Sustained Reduction in Blood Pressure in MODERATO II Control Patients After Crossover to BackBeat Cardiac Neuromodulation Therapy

Jul 28, 2021

NewAmsterdam Pharma Reports Positive Results from Phase 2 Study of Oral Obicetrapib Demonstrating Over 50% LDL-Lowering as an Adjunct to High-Intensity Statins

Jul 27, 2021

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

Jul 21, 2021

LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare Cardiovascular Diseases

Jul 20, 2021

Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardio-Metabolic Diseases

Jun 22, 2021

Imbria Pharmaceuticals Announces Enrolment of the First 10 Patients in IMPROVE-DiCE, an Exploratory Phase 2 Study Investigating the impact of IMB-1018972 on Cardiac Energetics, Metabolism and Function in Patients with Type 2 Diabetes

May 19, 2021

Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates

May 17, 2021

Orchestra BioMed™ Announces Clinical Data Showing Significant and Sustained Reduction in Systolic Blood Pressure Out to Two Years with BackBeat Cardiac Neuromodulation Therapy™

May 17, 2021

Imbria Pharmaceuticals Presents Phase 1 and Preclinical Data of IMB-1018972 (IMB-101), an Investigational Cardiac Mitotrope, at the American College of Cardiology 70th Annual Scientific Session and Expo

May 11, 2021

Verve Therapeutics to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT

Mar 12, 2021

Altasciences Conducts Preclinical Studies in Support of Verve Therapeutics’ Gene Editing Approach for Cardiovascular Disease

Mar 1, 2021

LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia Gene Therapy Program (LX2006)

Jan 19, 2021

Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease

Jan 13, 2021

Leading BioSciences Announces FDA Fast Track Designation Granted to LB1148 for the Treatment of Postoperative Gastrointestinal Dysfunction Associated with Pediatric Cardiovascular Surgery

Dec 15, 2020

HighTide Therapeutics to Present Phase 2 Results of HTD1801 in NASH Patients Co-Morbid with Type 2 Diabetes at NASH Summit

Dec 7, 2020

BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease

Aug 28, 2020

Harmony Biosciences Presents Efficacy And Safety Analyses For WAKIX (pitolisant) At Virtual SLEEP 2020

Jun 15, 2020

Data Presented at the 2020 ADA Scientific Sessions Show that Patients Treated with Cirius Therapeutics' MSDC-0602K Showed Improved Insulin Handling

May 7, 2020

HighTide Therapeutics Announces Positive Topline Results From Phase 2a Study of HTD1801 in NASH Patients

May 4, 2020

Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001

Mar 24, 2020

Leading BioSciences Announces Top Line Phase 2 Data Demonstrating LB1148 Achieves Primary Endpoint with Statistically Significant Improvement in Bowel Function Following Cardiovascular Surgery

Mar 10, 2020

Notice of Capital and Business Alliance Between Heartseed and MEDIPAL HOLDINGS

Feb 24, 2020

Institute of Human Virology and OncoImmune Launch Clinical Trial to Lessen Effects of HIV Later in Infection

Feb 5, 2020

Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications

Dec 8, 2019

Aurora Bio, Inc Announces Clinical Data on Lead Program, AUR01, a Novel Systemic Amyloidosis Imaging Tracer, at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition

Dec 5, 2019

Orchestra BioMed™ to Present at the Innovation in Cardiovascular Interventions Meeting and the CSI Focus D-HF Congress

Nov 22, 2019

Aurora Bio, Inc. Announces Clinical Data on Lead Program, AUR01, a Novel Systemic Amyloidosis Imaging Tracer, at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition

Nov 14, 2019

Bayer and Dewpoint Therapeutics partner to research new treatments for cardiovascular and gynecological diseases

Nov 14, 2019

Corvidia Therapeutics to Present New Data at the American Heart Association's Scientific Sessions 2019

Nov 13, 2019

Oleg Svanidze Appointed as Chief Medical Officer

Nov 5, 2019

Dystrogen Therapeutics Announces That Treatment With Dystrophin Expressing Chimeric (DEC) Cells Improves Cardiac Function in Preclinical Duchenne's Study

Sep 28, 2019

Orchestra BioMed Announces Late-Breaking Clinical Results Showing BackBeat Cardiac Neuromodulation Therapy™ Drives Significant Reduction in Systolic Blood Pressure

Sep 17, 2019

Eleusis Announces Published Research on Potential of Serotonin 2A Receptor Agonists to Impact Inflammation

Sep 4, 2019

Orchestra BioMed Receives CE Mark for BackBeat Cardiac Neuromodulation Therapy™ (CNT) for Hypertension

Aug 7, 2019

Numerate Receives $2 Million SBIR Phase II Award to Continue Research Using Its AI-Driven Discovery Platform to Identify New Antiarrhythmic Drug

Jul 10, 2019

Impel NeuroPharma to Present Data From INP104 Clinical Program at the 61st Annual Scientific Meeting of the American Headache Society

May 23, 2019

Orchestra BioMed™ Presents Clinical Data at EuroPCR 2019 Demonstrating Safety and Efficacy of BackBeat Cardiac Neuromodulation Therapy (CNT)

Mar 13, 2019

Tenaya Therapeutics Strengthens Leadership Team with Appointment of Two Biopharmaceutical Industry Veterans

Feb 27, 2019

Blackstone Life Sciences and Novartis Launch Anthos Therapeutics to Develop Innovative Medicines for Cardiovascular Disease

Jan 31, 2019

Inotrem Announces an Extension of Its License Agreement for the Biomarker Soluble TREM-1 to Cardiovascular Diseases

Dec 6, 2018

XyloCor Therapeutics Raises $17 Million in Series A Financing to Advance Gene Therapy Portfolio in Cardiovascular Disease

Nov 12, 2018

Cardurion Pharmaceuticals Presents Preclinical Data for CRD-733 at the American Heart Association Scientific Sessions and Announces Initiation of Phase 1b Study in Patients with Heart Failure

Nov 8, 2018

Orchestra BioMed™ Announces AHA 2018 Presentation on BackBeat Cardiac Neuromodulation Therapy (CNT)

Oct 23, 2018

Denovo Biopharma Licenses Global Rights to a Novel Late-Stage Oncology Drug from Sunesis Pharmaceuticals

Oct 10, 2018

Orchestra BioMed™ Strengthens Operations, RandD and Pharmaceutical Development Expertise with Key Leadership Team Additions

Sep 25, 2018

Orchestra BioMed™ Announces Presentation of Positive 2-Year Clinical Results and Program Update for BackBeat Cardiac Neuromodulation Therapy at TCT 2018

Aug 7, 2018

Sanifit Announces Completion of Enrollment in CaLIPSO - its Phase 2b Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialysis

Jun 25, 2018

Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis

Jun 18, 2018

Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions

Apr 16, 2018

Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate from Astellas

Jan 5, 2018

KBP Biosciences Raises $76 Million in Series A Financing and Appoints Brian P. McVeigh as Chief Executive Officer

Nov 28, 2017

NeuroproteXeon Announces Publication of Xenon Study to Lessen Cardiac Damage Following Out-of-Hospital Cardiac Arrest ("OHCA")

Nov 27, 2017

Diabetic Foot Ulcer Therapeutics Pipeline Analysis 2017 - Key Players are Lakewood Amedex, Edixomed and CardioVascular BioTherapeutics Inc

Nov 14, 2017

Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in ‘Nature’ Article

Nov 1, 2017

Quark Pharmaceuticals, Inc. Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting

Sep 14, 2017

G3 Pharmaceuticals to Pursue a Novel Class of Cardiovascular Pharmaceuticals

Aug 2, 2017

Takeda and Cardurion Pharmaceuticals Launch Cardiovascular Development Partnership

Jul 27, 2017

Quark Pharmaceuticals RNAi Drug Succeeds in Phase 2 Study to Prevent Acute Kidney Injury Following Cardiac Surgery

Jun 7, 2017

OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases

Jan 23, 2017

Sanifit Announces Enrollment of First Patient in CaLIPSO - a Phase IIb Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis

Dec 14, 2016

VistaGen Therapeutics Grants Exclusive Sublicense of Cardiac Stem Cell Technologies to BlueRock Therapeutics

Dec 1, 2016

Bicycle Therapeutics Announces Broad Partnership with AstraZeneca to Develop Bicyclic Peptides (Bicycles®)

Dec 1, 2016

Bicycle Therapeutics Announces Broad Partnership with AstraZeneca to Develop Bicyclic Peptides (Bicycles)

May 6, 2016

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

Mar 14, 2012

Numerate Forms Drug Discovery Collaboration with Merck to Utilize Numerate’s In Silico Drug Design Technology